Stopping Mounjaro for a week: what you need to decide before you do

What actually changes when you miss one week of tirzepatide

Mounjaro works by activating GIP and GLP-1 receptors, slowing gastric emptying and signalling fullness to the brain. That effect is sustained as long as the drug is present at a meaningful level. Tirzepatide's half-life of approximately five days means that, a week after your last injection, blood levels will have dropped substantially, roughly to a quarter of the post-dose peak. For most people that translates into a noticeable return of hunger, often stronger than expected, because the suppression they had grown used to starts lifting fairly quickly. Some people find this manageable; others find it unsettling, especially if they have been on a higher maintenance dose for a while, and if you are trying to work out how to tell if someone is on Mounjaro, the return of appetite during a gap is one of the signs that can make the picture less clear.

There is nothing in the NHS guidance on tirzepatide that describes a one-week gap as therapeutic or routinely recommended. The licensed schedule is a continuous once-weekly injection, titrated gradually. A planned pause sits outside that standard pattern, which is exactly why it warrants a conversation rather than a quiet decision made alone. It does not mean you cannot pause, it means the decision needs context.

For practical detail on how week-by-week treatment typically unfolds, the week five experience gives a useful picture of where most people are in their titration at that point.

The most common reasons people consider stopping for a week, and how each one shifts the calculus

Most people who ask about a one-week break fall into one of a handful of situations. Understanding which one fits you changes the answer.

Side effects that feel unmanageable. If nausea, vomiting or diarrhoea has become persistent rather than transient, pausing feels appealing. The honest response is that stopping for a week will not fix an underlying intolerance, it will only delay finding the right approach, which is usually a slower titration, dietary adjustment, or a frank clinical review. Restarting after the break often brings the symptoms back.

Supply interruption. This is the situation where a pause is least within your control. If your next pen has not arrived, you cannot inject what you do not have. The main risk here is not the gap itself but restarting at too high a dose after one; a two-week gap typically requires dropping back a dose level per the prescriber's guidance. A single week is a shorter gap and the restart decision is more nuanced, but it still needs a clinical view rather than a guess.

Surgery or a medical procedure. NHS England advises telling your anaesthetist and surgical team that you are on a GLP-1 medicine before any procedure. Some teams request a pause beforehand because of the effect on gastric emptying. If this applies to you, follow the instruction from your surgical team, they will tell you how long to stop and, importantly, when it is safe to restart.

Travel or practical logistics. Tirzepatide requires refrigeration between 2 and 8°C. If travel makes cold storage genuinely impossible, a short gap may be unavoidable. Check the Patient Information Leaflet for the precise room-temperature window before assuming you cannot take it with you, it is shorter than many people think. When a gap is unavoidable for logistical reasons, plan the restart with your prescriber in advance.

Restarting after one week: what the evidence and guidance say

After a gap of approximately one week, your prescriber will usually review whether you can continue at your current dose or whether stepping down makes sense. The tirzepatide overview covers the full licensed dose schedule from 2.5mg upward. One week is a shorter interruption than two, and many prescribers will continue at the same dose for a one-week gap in someone who was tolerating it well, but that is a clinical judgement, not a rule you can safely apply yourself.

What you should not do is simply assume the pause was neutral and carry on as though nothing happened. Gastrointestinal side effects are dose-dependent, and jumping back in at a higher dose after any break increases the chance they return with force. The guidance on restarting after a longer break makes the dose-stepping picture clearer, and the same caution applies even to a one-week gap at the higher end of the dose range.

There is also the question of what drove the pause in the first place. A week off for practical reasons is different from a week off because you were feeling unwell or questioning whether treatment is right for you. The latter is worth discussing openly. Our prescribers hear this question most weeks, and the conversation is almost always more productive than people expect. You can also check whether something specific has come up by reading through the frequently asked questions.

How to handle a planned pause through a clinically supervised service

If you are planning a break, the right step is to contact your prescriber before the gap begins, not after. At nume, every repeat order goes through a clinical review, a real prescriber, not automated software, reads your record each time. That means there is a natural moment to flag a planned pause and get a clear steer on how to restart safely.

For context on how the service works and the clinical team behind it, the clinical team profile is worth a look. And if cost or supply factors are part of your thinking, the background on Lilly's UK price changes may answer some of those questions. When your treatment does arrive (a plain box, a DPD notification on your phone, the pen waiting in the fridge) that consistency of supply is itself part of safe, uninterrupted care.

If you are thinking about starting treatment rather than pausing an existing course, you can start a free consultation and have a prescriber review your suitability the same day.